Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective

키워드

참고문헌 (61)

1. Summary of Vital Statistics. Number and rate of death by sex, by simple cause of death classification (per 100,000 population), , Ministry of Health, Labour and Welfare of Japan, ~ (2020)
2. Tateishi R, "Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma : A large retrospective multicenter cohort study", J Gastroenterol, 50, pp.350~360 (2015)
3. Nakano M, "Trends in hepatocellular carcinoma incident cases in Japan between 1996 and 2019", Sci Rep, 12, pp.1517~ (2022)
4. Takumi Kawaguchi, "MAFLD enhances clinical practice for liver disease in the Asia-Pacific region", Clinical and Molecular Hepatology, 28(2), pp.150~163 (2022), 대한간학회[DOI]
5. Rimini M, "Real-world data for atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: How does adherence to the imbrave150 trial inclusion criteria impact prognosis?", Target Oncol (2023)[DOI]
6. Hiraoka A, "Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib", Cancer Med, 12, pp.325~334 (2023)
7. Abou-Alfa GK, "Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma", NEJM Evid (2022)[DOI]
8. The Japan Society of Hepatology, "Clinical Practice Guidelines for Hepatocellular Carcinoma 2021 Version: JSH HCC Guidelines 2021", KANEHARA & Co., LT, ~ (2021)
9. Choi J, "Longitudinal assessment of three serum biomarkers to detect very early-stage hepatocellular carcinoma", Hepatology, 69, pp.1983~1994 (2019)
10. Kudo M, "Gd-EOB-DTPA-MRI could predict WNT", β-catenin mutation and resistance to immune checkpoint inhibitor therapy in hepatocellular carcinoma, 2020, pp.9, 479~490
11. Brierley JD, "TNM classification of malignant tumours" (2016), Wiley Blackwell
12. Kudo M, "General rules for the clinical and pathological study of primary liver cancer, nationwide follow-up survey and clinical practice guidelines : The outstanding achievements of the liver cancer study group of Japan", Dig Dis, 33, pp.765~770 (2015)
13. Taketomi A, "Hepatic resection for hepatocellular carcinoma in the era of molecular-targeted agents and immune checkpoint inhibitors in Japan", JMA J, 4, pp.241~245 (2021)
14. Tada T, "Role of hepatic resection in patients with intermediate-stage hepatocellular carcinoma : A multicenter study from Japan", Cancer Sci, 108, pp.1414~1420 (2017)
15. Kudo M, "Report of the 22nd nationwide follow-up survey of primary liver cancer in Japan(2012-2013)", Hepatol Res, 52, pp.5~66 (2022)
16. Takayama T, "Surgery versus radiofrequency ablation for small hepatocellular carcinoma : A randomized controlled trial(SURF Trial)", Liver Cancer, 11, pp.209~218 (2021)
17. Hiraki T, "Percutaneous radiofrequency ablation for pulmonary metastases from hepatocellular carcinoma : Results of a multicenter study in Japan", J Vasc Interv Radiol, 22, pp.741~748 (2011)
18. European Association for the Study of the Liver, "EASL Clinical Practice Guidelines : Management of hepatocellular carcinoma", J Hepatol, 69, pp.182~236 (2018)
19. Korean Liver Cancer Association (KLCA), "2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma", Clinical and Molecular Hepatology, 28(4), pp.583~705 (2022), 대한간학회
20. Kokudo N, "Clinical practice guidelines for hepatocellular carcinoma : The Japan Society of Hepatology 2017(4th JSH-HCC guidelines)2019 update", Hepatol Res, 49, pp.1109~1113 (2019)
21. Irie T, "Dense accumulation of lipiodol emulsion in hepatocellular carcinoma nodule during selective balloon-occluded transarterial chemoembolization : Measurement of balloon-occluded arterial stump pressure", Cardiovasc Intervent Radiol, 36, pp.706~713 (2013)
22. Shirono T, "Durable complete response is achieved by balloonoccluded transcatheter arterial chemoembolization for hepatocellular carcinoma", Hepatol Commun, 6, pp.2594~2604 (2022)
23. Hiraoka A, "Hepatic function during repeated TACE procedures and prognosis after introducing sorafenib in patients with unresectable hepatocellular carcinoma: Multicenter analysis", Dig Dis, 35, pp.602~610 (2017)
24. Kudo M, "A novel treatment strategy for patients with intermediate-stage HCC who are not suitable for TACE : Upfront systemic therapy followed by curative conversion", Liver Cancer, 10, pp.539~544 (2021)
25. Arizumi T, "Time to transcatheter arterial chemoembolization refractoriness in patients with hepatocellular carcinoma in kinki criteria stages B1 and B2", Dig Dis, 35, pp.589~597 (2017)
26. Shimose S, "Indication of suitable transarterial chemoembolization and multikinase inhibitors for intermediate stage hepatocellular carcinoma", Oncol Lett, 19, pp.2667~2676 (2020)
27. Kudo M, "Lenvatinib as an initial treatment in patients with intermediatestage hepatocellular carcinoma beyond up-to-seven criteria and child-pugh a liver function: A proof-of-concept study", Cancers(Basel), 11, pp.1084~ (2019)
28. Kudo M, "Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial", Gut, 69, pp.1492~1501 (2020)
29. Shimose S, "Alternating lenvatinib and trans-arterial therapy prolongs overall survival in patients with inter-mediate stage hepatocellular carcinoma: A propensity score matching study", Cancers(Basel), 13, pp.160~ (2021)
30. Kudo M, "A changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma : Asia-Pacific Primary Liver Cancer Expert Consensus Statements", Liver Cancer, 9, pp.245~260 (2020)
31. Vogel A, "Updated treatment recommendations for hepatocellular carcinoma(HCC)from the ESMO Clinical Practice Guidelines", Ann Oncol, 32, pp.801~805 (2021)
32. Llovet JM, "Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference", Hepatology, 73(Suppl 1), pp.158~191 (2021)
33. Kei Moriya, "Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients", Clinical and Molecular Hepatology, 25(4), pp.381~389 (2019), 대한간학회
34. Ueshima K, "Clinical practice guidelines for hepatic arterial infusion chemotherapy with a port system proposed by the Japanese Society of Interventional Radiology and Japanese Society of Implantable Port Assisted Treatment", Liver Cancer, 11, pp.407~425 (2022)
35. Hideki Iwamoto, "Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity", Clinical and Molecular Hepatology, 29(3), pp.593~604 (2023), 대한간학회
36. Ikeda M, "Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma : Randomized phase II trial", Ann Oncol, 27, pp.2090~2096 (2016)
37. Kudo M, "Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): A randomised, open label, phase 3 trial", Lancet Gastroenterol Hepatol, 3, pp.424~432 (2018)
38. Kondo M, "Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma : SCOOP-2 trial", BMC Cancer, 19, pp.954~ (2019)
39. Shibuya K, "Efficacy and safety of 4 fractions of carbon-ion radiation therapy for hepatocellular carcinoma : A Prospective Study", Liver Cancer, 11, pp.61~74 (2021)
40. Kimura T, "The current role of stereotactic body radiation therapy(SBRT)in hepatocellular carcinoma(HCC)", Cancers(Basel), 14, pp.4383~ (2022)
41. Tanaka T, "Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice", Hepatol Res, 52, pp.773~783 (2022)
42. Maesaka K, "Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma", Hepatol Res, 52, pp.630~640 (2022)
43. Niizeki T, "Comparison of efficacy and safety of atezolizumab plus bevacizumab and lenvatinib as first-line therapy for unresectable hepatocellular carcinoma : A propensity score matching analysis", Target Oncol, 17, pp.643~653 (2022)
44. Casadei-Gardini A, "Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma : A large real-life worldwide population", Eur J Cancer, 180, pp.9~20 (2023)
45. Kudo M, "Atezolizumab plus bevacizumab followed by curative conversion(ABC Conversion)in patients with unresectable, TACE-unsuitable intermediate-stage hepatocellular carcinoma", Liver Cancer, 11, pp.399~406 (2022)
46. Kudo M, "Achievement of cancer- and treatment-free status by atezolizumab plus bevacizumab combined with or without curative conversion in patients with transarterial chemoembolizationunsuitable, intermediate-stage hepatocellular carcinoma: A multicenter cohort study", J Clin Oncol, 41(Suppl. Abstract no. 535) (2023)
47. Hideki Iwamoto, "Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma", Clinical and Molecular Hepatology, 28(3), pp.575~579 (2022), 대한간학회[DOI]
48. Iwamoto H, "Weekends-off lenvatinib for unresectable hepatocellular carcinoma improves therapeutic response and tolerability toward adverse events", Cancers(Basel), 12, pp.1010~ (2020)
49. Kim Y, "Sorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma", Eur J Gastroenterol Hepatol, 35, pp.191~197 (2023)
50. Peng Z, "Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma : A phase III, randomized clinical trial(LAUNCH)", J Clin Oncol, 41, pp.117~127 (2023)
51. Rimini M, "Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma : An international propensity score matching analysis", ESMO Open, 7, pp.100591~ (2022)
52. Ueshima K, "Transcatheter arterial chemoembolization therapy in combination strategy with lenvatinib in patients with unresectable hepatocellular carcinoma(TACTICS-L)in Japan : Final analysis", J Clin Oncol (2022)[DOI]
53. Shimose S, "Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real-world data", Hepatol Res, 53, pp.116~126 (2023)
54. Kuzuya T, "Clinical outcomes of ramucirumab as posttreatment following atezolizumab", bevacizumab combination therapy in advanced hepatocellular carcinoma, 2022, pp.42, 1905~1910
55. Komatsu S, "Current role of atezolizumab plus bevacizumab therapy in the sequential treatment of unresectable hepatocellular carcinoma", Anticancer Res, 42, pp.1403~1412 (2022)
56. Kato N, "Cabozantinib in Japanese patients with advanced hepatocellular carcinoma : Final results of a multicenter phase II study", Hepatol Res (2023)[DOI]
57. Calderaro J, "Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma", J Hepatol, 76, pp.1348~1361 (2022)
58. Murai H, "Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma", Hepatology, 77, pp.77~91 (2023)
59. Sato M, "Artificial intelligence in the diagnosis and management of hepatocellular carcinoma", J Gastroenterol Hepatol, 36, pp.551~560 (2021)
60. Nishida N, "Artificial intelligence (AI)models for the ultrasonographic diagnosis of liver tumors and comparison of diagnostic accuracies between AI and human experts", J Gastroenterol, 57, pp.309~321 (2022)
61. Makkouk A, "Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3(GPC-3)-specific chimeric antigen receptor(CAR)and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma", J Immunother Cancer, 9, pp.e003441~ (2021)

관련 논문AI추천